These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1429 related articles for article (PubMed ID: 18439766)

  • 1. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
    Douillard JY; Rosell R; De Lena M; Riggi M; Hurteloup P; Mahe MA;
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):695-701. PubMed ID: 18439766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
    Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
    Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
    Keller SM; Adak S; Wagner H; Herskovic A; Komaki R; Brooks BJ; Perry MC; Livingston RB; Johnson DH
    N Engl J Med; 2000 Oct; 343(17):1217-22. PubMed ID: 11071672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
    Pisters KM; Evans WK; Azzoli CG; Kris MG; Smith CA; Desch CE; Somerfield MR; Brouwers MC; Darling G; Ellis PM; Gaspar LE; Pass HI; Spigel DR; Strawn JR; Ung YC; Shepherd FA; ;
    J Clin Oncol; 2007 Dec; 25(34):5506-18. PubMed ID: 17954710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
    Johnson BE; Rabin MS
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5022s-5026s. PubMed ID: 16000607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.
    Wakelee HA; Stephenson P; Keller SM; Wagner H; Herskovic A; Komaki R; Marks RS; Perry MC; Livingston RB; Johnson DH;
    Lung Cancer; 2005 Jun; 48(3):389-97. PubMed ID: 15893008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Postoperative adjuvant therapy for 189 patients with completely resected non-small cell lung cancer of stage III(A)].
    Li Q; Gao JM; Liang PY; Xie FY; Liu GZ
    Ai Zheng; 2004 Nov; 23(11 Suppl):1463-6. PubMed ID: 15566658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
    Wakelee H; Dubey S; Gandara D
    Oncologist; 2007 Mar; 12(3):331-7. PubMed ID: 17405898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy.
    Bischof M; Debus J; Herfarth K; Muley T; Kappes J; Storz K; Hoffmann H
    Strahlenther Onkol; 2007 Dec; 183(12):679-84. PubMed ID: 18040612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
    Alam N; Shepherd FA; Winton T; Graham B; Johnson D; Livingston R; Rigas J; Whitehead M; Ding K; Seymour L
    Lung Cancer; 2005 Mar; 47(3):385-94. PubMed ID: 15713522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial.
    Dunant A; Pignon JP; Le Chevalier T
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5017s-5021s. PubMed ID: 16000606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
    Dediu M; Horvat T; Tarlea A; Anghel R; Cordos I; Miron G; Iorga P; Alexandru A; Nistor C; Grozavu C; Savu C
    Lung Cancer; 2005 Jan; 47(1):93-101. PubMed ID: 15603859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer.
    Park JH; Lee CT; Lee HW; Baek HJ; Zo JI; Shim YM
    Eur J Cardiothorac Surg; 2005 Jun; 27(6):1086-91. PubMed ID: 15896623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
    Jaklitsch MT; Herndon JE; DeCamp MM; Richards WG; Kumar P; Krasna MJ; Green MR; Sugarbaker DJ
    J Surg Oncol; 2006 Dec; 94(7):599-606. PubMed ID: 17039491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
    Waller D; Peake MD; Stephens RJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG
    Eur J Cardiothorac Surg; 2004 Jul; 26(1):173-82. PubMed ID: 15200998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M;
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.